Global Idiopathic Pulmonary Fibrosis (IPF) Competitor Landscape 2018: Analysis of Current & Potential Future Product Positioning

NEXT STORY
Amicus Therapeutics Announces Positive data in Pompe Disease Phase 1/2 Study for Up to 24 Months at 15th Annual WORLDSymposium™
PREV STORY
AVRA Medical Robotics, Inc. issues CEO letter to Shareholders
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

CytomX Therapeutics to Announce Full-Year 2017 Financial Results and Host Operational Update Webcast Conference Call

SOUTH SAN FRANCISCO, Calif., Feb. 22, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), ...

author_avatar
NASDAQ Market News

NeuroDerm Presents ND0612H Phase II Trial Results in Late-Breaking Poster Session at the 21st International Congress of Parkinson’s Disease and Movement Disorders

-ND0612H achieved a complete reduction of OFF-time to zero in 42% of patients treated ...

author_avatar
NASDAQ Market News

Apricus Biosciences Provides Corporate Update and Second Quarter 2017 Financial Results

Vitaros Drug-Device Human Factor Studies Successfully Completed Vitaros U.S. NDA Final Draft Completed with ...

author_avatar
NASDAQ Market News